Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant
- Authors
- Nam, Ki-Woong; Kim, Chi Kyung; Kim, Tae Jung; An, Sang Joon; Oh, Kyungmi; Ko, Sang-Bae; Yoon, Byung-Woo
- Issue Date
- Dec-2017
- Publisher
- ELSEVIER SCIENCE BV
- Keywords
- Ischemic stroke; cancer; hypercoagulability; NOAC; anticoagulation; prognosis
- Citation
- JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, v.26, no.12, pp 2976 - 2980
- Pages
- 5
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
- Volume
- 26
- Number
- 12
- Start Page
- 2976
- End Page
- 2980
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/4381
- DOI
- 10.1016/j.jstrokecerebrovasdis.2017.07.029
- ISSN
- 1052-3057
1532-8511
- Abstract
- Background: Low-molecular weight heparin (LMWH) was shown to be effective and safe in treating venous thromboembolism, and generally used for stroke in cancer patients, but its effects on stroke are unclear. We compared clinical outcomes between LMWH and new oral anticoagulant (NOAC) in patients with cancer-related stroke. Methods: We enrolled patients with cryptogenic ischemic stroke with active cancer who were treated with LMWH or NOAC between May 2012 and June 2015. The clinical outcomes, including early neurologic deterioration, early radiologic recurrence, 3-month modified Rankin scale score, 90-day mortality, cardio-cerebrovascular recurrence, and bleeding complications, were compared. Results: Among 48 patients, 7 patients were treated with NOAC, and the remaining 41 patients with LMWH. Overall, the participants presented poor outcomes, including 20 (42%) early neurologic deteriorations, 28 (58%) early radiologic recurrences, 34 (71%) poor modified Rankin scale scores, 27 (56%) 90-day mortality events, 24 (50%) cardio-cerebrovascular recurrences, and 18 (38%) bleeding complications, that led to a change or temporary hold in medication in 12 cases. No statistical differences were found between the 2 groups in terms of demographic, clinical, or cardiovascular risk factors and clinical outcomes. Conclusions: NOAC showed the similar clinical outcomes and safety compared with LMWH in the treatment of cryptogenic ischemic stroke in active cancer patients.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Neurology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.